What did the American Diabetes Association recommend for LDL‑cholesterol targets in adults with diabetes last year?

ADA LDL Cholesterol Goals in Diabetics

The American Diabetes Association (ADA) recommends an LDL cholesterol target of <70 mg/dL (<1.8 mmol/L) for adults with diabetes who have established cardiovascular disease or are at higher cardiovascular risk, with high-intensity statin therapy to achieve ≥50% LDL-C reduction from baseline. 1

Primary Prevention (No Established ASCVD)

Age 40-75 Years

• Moderate-intensity statin therapy is recommended for all adults with diabetes aged 40-75 years, regardless of baseline cardiovascular risk 1
• High-intensity statin therapy should be prescribed for those with multiple ASCVD risk factors to achieve ≥50% LDL-C reduction and target LDL-C <70 mg/dL 1
• Risk-enhancing factors that favor high-intensity therapy include: family history of premature ASCVD, albuminuria ≥30 mg/mg, eGFR <60 mL/min/1.73 m², retinopathy, neuropathy, ankle-brachial index <0.9, LDL-C ≥160 mg/dL, or metabolic syndrome 1

Age <40 Years

• Moderate-intensity statin therapy may be reasonable for those with long-standing diabetes (type 2 for ≥10 years or type 1 for ≥20 years) plus additional ASCVD risk factors 1

Age >75 Years

• Continue statin therapy if already established 1

Secondary Prevention (Established ASCVD)

For all adults with diabetes and established ASCVD, the treatment approach is aggressive:

• High-intensity statin therapy is mandatory to target LDL-C <70 mg/dL with ≥50% reduction from baseline 1
• For very high-risk patients (multiple ASCVD events or one event plus multiple high-risk conditions), target LDL-C <55 mg/dL (<1.4 mmol/L) 1
• Very high-risk conditions include: age ≥65 years, heterozygous familial hypercholesterolemia, prior PCI/CABG, hypertension, CKD, current smoking, heart failure history, or LDL-C ≥100 mg/dL on maximal statin plus ezetimibe 1

Combination Therapy Algorithm

When LDL-C remains >70 mg/dL on maximally tolerated statin:

1. Add ezetimibe first (preferred due to proven cardiovascular benefit and lower cost) 1
2. If LDL-C still >70 mg/dL (or >55 mg/dL for very high-risk), add PCSK9 inhibitor 1
3. This stepwise approach is supported by simulation analyses showing most patients achieve goal with statin plus ezetimibe 1

Key Algorithmic Considerations

The treatment intensity should be determined by:

• Presence or absence of established ASCVD (secondary vs. primary prevention)
• Number of ASCVD risk factors (determines moderate vs. high-intensity statin)
• Age category (40-75 years have strongest evidence)
• On-treatment LDL-C levels (determines need for combination therapy)

Important Caveats

• The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA guidelines align closely with ADA 2019 recommendations, providing strong consensus 1
• Cost-effectiveness of PCSK9 inhibitors has improved as prices declined, but ezetimibe remains preferred as initial add-on therapy 1
• Statin therapy is contraindicated in pregnancy 1
• Monitor lipid profiles at initiation, 4-12 weeks after dose changes, and annually thereafter to assess response and adherence 1

Printable summary: For diabetes without ASCVD (age 40-75): moderate-intensity statin, escalate to high-intensity if multiple risk factors present, target <70 mg/dL. For diabetes with ASCVD: high-intensity statin targeting <70 mg/dL (or <55 mg/dL if very high-risk), add ezetimibe if needed, then PCSK9 inhibitor if still above goal. 1